Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Does Novartis AG (ADR) (NVS) Pass Buffett’s Test?

Page 1 of 2

We’d all like to invest like the legendary Warren Buffett, turning thousands into millions or more. Buffett analyzes companies by calculating return on invested capital, or ROIC, to help determine whether a company has an economic moat — the ability to earn returns on its money above that money’s cost.

Warren Buffett

In this series, we examine several companies in a single industry to determine their ROIC. Let’s take a look at Novartis AG (ADR) (NYSE:NVS) and three of its industry peers, to see how efficiently they use cash.

Of course, it’s not the only metric in value investing, but ROIC may be the most important one. By determining a company’s ROIC, you can see how well it’s using the cash you entrust to it and whether it’s actually creating value for you. Simply put, it divides a company’s operating profit by how much investment it took to get that profit. The formula is:

ROIC = net operating profit after taxes / Invested capital

(Get further detail on the nuances of the formula.)

This one-size-fits-all calculation cuts out many of the legal accounting tricks (such as excessive debt) that managers use to boost earnings numbers, and it provides you with an apples-to-apples way to evaluate businesses, even across industries. The higher the ROIC, the more efficiently the company uses capital.

Ultimately, we’re looking for companies that can invest their money at rates that are higher than the cost of capital, which for most businesses is between 8% and 12%. Ideally, we want to see ROIC above 12%, at a minimum, and a history of increasing returns, or at least steady returns, which indicate some durability to the company’s economic moat.

Here are the ROIC figures for Novartis AG (ADR) (NYSE:NVS) and three industry peers over a few periods.

Company TTM 1 Year Ago 3 Years Ago 5 Years Ago
Novartis 11% 10.7% 15.5% 13%
Merck & Co., Inc. (NYSE:MRK) 10.1% 12.8% 6.9% 19.9%
GlaxoSmithKline plc (ADR) (NYSE:GSK) 17.6% 26.6% 26.4% 28.7%
Pfizer Inc. (NYSE:PFE) 10.8% 9.4% 8.4% 15.7%

Source: S&P Capital IQ. TTM = trailing 12 months.

Of the listed companies, only GlaxoSmithKline plc (ADR) (NYSE:GSK) meets our 12% threshold for attractiveness. However, its returns have declined by more than 11 percentage points from five years ago. Novartis AG (ADR) (NYSE:NVS) and Pfizer Inc. (NYSE:PFE) both come close to meeting our 12% threshold, but they’ve also seen some declines in their returns from five years ago. However, all of these companies offer healthy dividends: Novartis AG (ADR) (NYSE:NVS) at 3.4%, Merck & Co., Inc. (NYSE:MRK) at 3.6%, GlaxoSmithKline at 4.2%, and Pfizer Inc. (NYSE:PFE) at 3.3%.

Novartis AG (ADR) (NYSE:NVS) is active in both the proprietary and the generic drug markets. This diversity offers key benefits. While proprietary drugs can help a company’s profits skyrocket, they also expose businesses to rapid drops in revenue as patents expire and regulatory changes cause consumers to pursue lower-cost options. While Novartis AG (ADR) (NYSE:NVS)’ involvement in the generic drug market may not offer the same growth potential, it can help the company maintain more steady revenues.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!